VEENAT 400 TABLET

Veenat 400 Tablet is a targeted anticancer medicine containing imatinib mesylate, a well-established oral tyrosine kinase inhibitor (TKI). It is widely prescribed for the treatment of chronic myeloid leukemia (CML), Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), and gastrointestinal stromal tumors (GIST). This tablet plays a crucial role in modern targeted cancer therapy by addressing the molecular causes of tumor growth.

Veenat works by selectively inhibiting abnormal tyrosine kinase proteins responsible for uncontrolled cancer cell proliferation. Blocking these signaling pathways, it helps slow disease progression, control tumor growth, and improve treatment outcomes. The oral tablet form allows for convenient daily dosing, making it suitable for long-term cancer management under strict medical supervision.

Manufactured in WHO-GMP certified facilities, Veenat 400 mg Tablet ensures consistent quality, safety, and therapeutic efficacy. It is a prescription-only oncology medicine and should be used strictly as advised by a qualified oncologist. Due to its proven effectiveness, Veenat is widely supplied for hospital use, specialty pharmacies, and international export markets.

Product Features

• Oral tyrosine kinase inhibitor (TKI)
• Contains Imatinib 400 mg
• Used in leukemia and GIST treatment
• Targets BCR-ABL, KIT, and PDGFR pathways
• Once-daily oral dosing (as prescribed)
• Suitable for long-term cancer management
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Blocks abnormal tyrosine kinase activity to control cancer growth
• Helps slow the progression of leukemia and GIST
• Targets BCR-ABL, KIT, and PDGFR pathways at the molecular level
• Supports effective long-term oral cancer therapy under supervision